You are here

Phase I study of Relapsed / Refractory Multiple Myeloma

Last updated on June 13, 2019

FOR MORE INFORMATION
Study Location
Baylor University Medical Center
Dallas, Texas, 75246 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Multiple Myeloma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with relapse/ refractory multiple myeloma

- Performance Status of 0- 2 (unless due to bone pain)

- Adequate bone marrow, kidney and liver function

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- History of active autoimmune disorders

- Active and clinically significant bacterial, fungal, or viral infection

- Major surgery within 4 weeks of study treatment start

- Radiation therapy within 2 weeks of study treatment start

- Less than 30 days since last dose of anti CD38 therapy, elotuzumab or other anti-CD319
therapy or less than 5 half-lives since last dose of previous systemic therapy.

- Stem cell transplant (autologous or allogeneic) within 100 days of study treatment
start

Trial Details
Administration
The form in which the study drug will be delivered to the patient's body.
Intravenous injections
Subcutaneous injections
Placebo
A placebo often looks like the investigational medication, but it has no active ingredient in it.
A placebo is not used in this trial
Duration
The time commitment for participation in the study.
Follow up: 4 weeks
Screening: Range 2 weeks
Treatment: Range 4 weeks
Site Visits
Follow up: 1 visits
Screening: Up to 2 visits
Treatment: Up to 10 visits
Prior Approval
The study drug has not been approved yet.
Post-Trial Access to Study Drug
Not planned
Trial Procedures
Biopsy
Blood test
Electrocardiogram (ECG)
Physical examination
Urine test
Vital signs and measurements
Other
NCT03269136
Pfizer
Recruiting
Phase I study of Relapsed / Refractory Multiple Myeloma

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Multiple Myeloma
NCT03269136
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now